What is CytoDyn based on?

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells.

What is CytoDyn's primary endpoint?

In February 2018, Cytodyn Inc reported that the primary endpoint was achieved in the PRO 140 pivotal combination therapy trial in HIV infection and will continue for an additional 24 weeks (end of August 2018) with PRO 140 weekly subcutaneous injections and optimized ART.

Will CytoDyn approve Leronlimab for emergency use?

In recent weeks, several national health agencies were in discussions with CytoDyn (OTCMKTS: CYDY) to approve Leronlimab, the monoclonal antibody that CytoDyn owns, for emergency use. On March 5 th, CytoDyn released Phase IIb/III testing results. Sadly, data was mixed, creating confusion among investors.

Is CytoDyn causing a sell-off?

In finance, everyone’s trying to make money. So, if you’re short CYDY and have the resources, you’ll engage in behaviors designed to induce sell-offs. In February 2021, Adam Feuerstein, a highly-regarded finance journalist with STAT News, turned his sights on CytoDyn.